FGF21 has been shown to activate AMP-activated protein kinase (AMPK) in adipocytes (134) and hepatocytes (135) which prevents hepatocyte apoptosis (136) and reduces ER-stress in NASH (137). The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatohepatitis.